
Accuray (ARAY) Stock Forecast & Price Target
Accuray (ARAY) Analyst Ratings
Bulls say
Accuray is a radiation oncology company with a strong focus on precision and accuracy in treating cancer and tumors using its unique CyberKnife technology. However, the company's financial performance has been impacted by geopolitical uncertainty and macroeconomic headwinds, causing it to trade at a discount to its peers. While management has implemented a transformation plan to improve profitability, the company's ability to achieve consistent revenue growth remains a key concern. As a result, BTIG has maintained a Neutral rating on the stock and has reduced its price target to $2.
Bears say
Accuray is facing multiple challenges, including geopolitical uncertainty in the Middle East, declining revenues due to lower product and service orders, and difficulties in commercial execution and profitability. These challenges have led us to revise our outlook to negative and to reduce our forecasted revenues, gross orders, and EBITDA for both the current year and the outyears. We also see risks from geopolitical tensions, tariffs, supply chain challenges, and potential delays in product development.
This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.
Accuray (ARAY) Analyst Forecast & Price Prediction
Start investing in Accuray (ARAY)
Order type
Buy in
Order amount
Est. shares
0 shares